Friday, January 29, 2021 Daily Archives

eBook: Formulation, Fill–Finish — Biopharmaceutical Drug-Product Trends and Technologies

by and

As with many other aspects of biopharmaceutical development, evolving technologies are transforming drug-product development and manufacturing. In a November 2020 report on the Informa Connect “Drug Delivery Partnerships†meeting, BPI senior technical editor Cheryl Scott reviewed how new delivery-device technologies are bringing together companies with disparate expertise to serve patients with chronic conditions better than ever before. The ever-increasing capabilities of electronics and information technology (IT) not only are enabling development of “smart†delivery devices, but also improving the potential…

January 29, 2021

Bioprocessing ‘running hot’ for Danaher with $1.3bn COVID windfall to come

by

Danaher Corporation reports double-digit sales growth at its bioprocess units Pall and Cytiva, inflated by COVID-related dividends it says will continue this year. For the full year 2020, Danaher Corporation reported net sales of $22.3 billion, a 24.5% increase on the previous year. Life sciences pulled in $10.6 billion of this, up 52% on 2019. While Danaher does not detail its individual business financial figures, the contributions from Cytiva – acquired for $21 billion last April –  and Pall Biotech…

January 29, 2021

Bio-CDMOs remain in the small molecule game despite divestments

by

While CDMOs continue to expand biologics and advanced therapy services recent divestments from Lonza and Catalent do not indicate the abandonment of small molecules capabilities. For two of the largest contract development and manufacturing organizations (CDMOs), the new year really did follow the old adage ‘out with the old…’ Catalent began 2021 by agreeing to sell its Blow-Fill-Seal (BFS) sterile contract development and manufacturing business, based at a single site in Woodstock, Illinois, to SK Capital Partners. The CDMO said…

January 29, 2021